Wound Care

Wound care is the indication where protein-enriched PRP has the strongest direct evidence — because it is the only field where the actual ProtSmart filter platform has been used in a published clinical study.

Mazzucco et al. (2024) treated 10 patients with severe Stage III–IV sacral pressure ulcers using protein-enriched filtered PRP (PEFPRP) prepared with a ProtSmart-based ultrafiltration device (Medica S.p.A.). These were patients with advanced neurological disability for whom surgical options were limited. The concentrate achieved platelet concentrations of 1–1.2 million per microliter and plasma protein concentrations of 12–16 g/dL — approximately twice the normal level. All 10 patients showed improvement, with mean wound surface area reduction of 52% at 6 weeks and PUSH score improvement of 21%.

The authors explicitly stated that PEFPRP “collects and concentrates platelets AND all the proteins present in the plasma and released by platelets, ensuring the complete and total collection of all PRP molecules that are normally lost during centrifugation.”

This matters because chronic wounds fail in large part due to protease imbalance — elevated MMPs degrade the extracellular matrix faster than it can be rebuilt. Concentrated A2M provides broad-spectrum protease inhibition. Concentrated fibrinogen polymerizes into a dense fibrin scaffold that serves as the provisional matrix for cell migration and sustained growth factor release. Concentrated fibronectin mediates epithelial cell adhesion and migration across the wound bed. These are the proteins that every centrifugation-based PRP system discards with platelet-poor plasma.

autologIX uses the same manufacturer’s ultrafiltration platform (Medica S.p.A., MediSulfone® polysulfone membrane, 15 kDa MWCO) with the ProtSmart 6 device.

Clinical studies investigating autologIX outcomes are in development.